Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTELOPE: Atezolizumab vs Pembrolizumab in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05689671Phase 4Active, not recruiting
- Sponsor
- Nikolaj Frost
- Start
- Dec 2023
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Nikolaj Frost. Started Dec 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05689671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689671.